Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job

U.S. drugmaker shares fell after Trump appointed Robert F. Kennedy Jr. to lead health, raising investor concerns over vaccine policies and agency oversight.

Earnings call: Church & Dwight reports a 3.8% increase in sales

Church & Dwight's Q3 2024 results show strong sales growth, despite challenges in gummy vitamins. The company anticipates continued growth fueled by innovation and increased marketing efforts.

Church & Dwight beats Q3 estimates, raises full-year outlook

Church & Dwight Co. exceeded Q3 expectations, boosting its full-year outlook; earnings per share hit $0.79, with revenue up 3.8% to $1.51 billion, driven by organic growth.

Morning Bid: Amazon calms the horses, payrolls due